SALT AND CRYSTAL FORM OF EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF

The present invention relates to a salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DING, Lieming, TANG, Jian, WANG, Jiabing, LIU, Xiangyong, QIU, Changyong, CHEN, Liang
Format:	Patent
Sprache:	chi ; eng ; fre
Schlagworte:	ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	DING, Lieming TANG, Jian WANG, Jiabing LIU, Xiangyong QIU, Changyong CHEN, Liang
description	The present invention relates to a salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms. La présente invention concerne une forme saline et une forme cristalline d'un inhibiteur D'EGFR, et une composition et l'utilisation associées. La forme saline et la forme cristalline de l'inhibiteur de l'EGFR selon la formule I de la présente invention peuvent être utilisées pour traiter ou prévenir des maladies ou affections médicales médiées par le récepteur du facteur de croissance épidermique (par ex. des mutants d'activation L858R, des mutants d'activation de délétion à l'exon 19, des mutants de résistance T790M et des mutants rés
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023020600A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023020600A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023020600A13</originalsourceid><addsrcrecordid>eNrjZPAIdvQJUXD0c1FwDooMDnH0UXDzD_JV8HdTcHV3C1Lw9PPwdPIM8Q_Sgajx9w3wD_YM8fT3A_NDg10VQjxcg1z93XgYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkbGBkYGZgYGjoTFxqgB-iS07</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>SALT AND CRYSTAL FORM OF EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF</title><source>esp@cenet</source><creator>DING, Lieming ; TANG, Jian ; WANG, Jiabing ; LIU, Xiangyong ; QIU, Changyong ; CHEN, Liang</creator><creatorcontrib>DING, Lieming ; TANG, Jian ; WANG, Jiabing ; LIU, Xiangyong ; QIU, Changyong ; CHEN, Liang</creatorcontrib><description>The present invention relates to a salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms. La présente invention concerne une forme saline et une forme cristalline d'un inhibiteur D'EGFR, et une composition et l'utilisation associées. La forme saline et la forme cristalline de l'inhibiteur de l'EGFR selon la formule I de la présente invention peuvent être utilisées pour traiter ou prévenir des maladies ou affections médicales médiées par le récepteur du facteur de croissance épidermique (par ex. des mutants d'activation L858R, des mutants d'activation de délétion à l'exon 19, des mutants de résistance T790M et des mutants rés</description><language>chi ; eng ; fre</language><subject>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM ; CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230223&DB=EPODOC&CC=WO&NR=2023020600A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230223&DB=EPODOC&CC=WO&NR=2023020600A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DING, Lieming</creatorcontrib><creatorcontrib>TANG, Jian</creatorcontrib><creatorcontrib>WANG, Jiabing</creatorcontrib><creatorcontrib>LIU, Xiangyong</creatorcontrib><creatorcontrib>QIU, Changyong</creatorcontrib><creatorcontrib>CHEN, Liang</creatorcontrib><title>SALT AND CRYSTAL FORM OF EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF</title><description>The present invention relates to a salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms. La présente invention concerne une forme saline et une forme cristalline d'un inhibiteur D'EGFR, et une composition et l'utilisation associées. La forme saline et la forme cristalline de l'inhibiteur de l'EGFR selon la formule I de la présente invention peuvent être utilisées pour traiter ou prévenir des maladies ou affections médicales médiées par le récepteur du facteur de croissance épidermique (par ex. des mutants d'activation L858R, des mutants d'activation de délétion à l'exon 19, des mutants de résistance T790M et des mutants rés</description><subject>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM</subject><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPAIdvQJUXD0c1FwDooMDnH0UXDzD_JV8HdTcHV3C1Lw9PPwdPIM8Q_Sgajx9w3wD_YM8fT3A_NDg10VQjxcg1z93XgYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkbGBkYGZgYGjoTFxqgB-iS07</recordid><startdate>20230223</startdate><enddate>20230223</enddate><creator>DING, Lieming</creator><creator>TANG, Jian</creator><creator>WANG, Jiabing</creator><creator>LIU, Xiangyong</creator><creator>QIU, Changyong</creator><creator>CHEN, Liang</creator><scope>EVB</scope></search><sort><creationdate>20230223</creationdate><title>SALT AND CRYSTAL FORM OF EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF</title><author>DING, Lieming ; TANG, Jian ; WANG, Jiabing ; LIU, Xiangyong ; QIU, Changyong ; CHEN, Liang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023020600A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng ; fre</language><creationdate>2023</creationdate><topic>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM</topic><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>DING, Lieming</creatorcontrib><creatorcontrib>TANG, Jian</creatorcontrib><creatorcontrib>WANG, Jiabing</creatorcontrib><creatorcontrib>LIU, Xiangyong</creatorcontrib><creatorcontrib>QIU, Changyong</creatorcontrib><creatorcontrib>CHEN, Liang</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DING, Lieming</au><au>TANG, Jian</au><au>WANG, Jiabing</au><au>LIU, Xiangyong</au><au>QIU, Changyong</au><au>CHEN, Liang</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>SALT AND CRYSTAL FORM OF EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF</title><date>2023-02-23</date><risdate>2023</risdate><abstract>The present invention relates to a salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms. La présente invention concerne une forme saline et une forme cristalline d'un inhibiteur D'EGFR, et une composition et l'utilisation associées. La forme saline et la forme cristalline de l'inhibiteur de l'EGFR selon la formule I de la présente invention peuvent être utilisées pour traiter ou prévenir des maladies ou affections médicales médiées par le récepteur du facteur de croissance épidermique (par ex. des mutants d'activation L858R, des mutants d'activation de délétion à l'exon 19, des mutants de résistance T790M et des mutants rés</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	chi ; eng ; fre
recordid	cdi_epo_espacenet_WO2023020600A1
source	esp@cenet
subjects	ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	SALT AND CRYSTAL FORM OF EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A17%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DING,%20Lieming&rft.date=2023-02-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023020600A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true